Description
Product Characteristics:
Inhibits NF-kappa-B activation by blocking the interaction of RIPK1 with its downstream effector NEMO/IKBKG. Forms a ternary complex with NFKB1 and MAP3K8 but appears to function upstream of MAP3K8 in the TLR4 signaling pathway that regulates MAP3K8 activation. Involved in activation of the MEK/ERK signaling pathway during innate immune response, this function seems to be stimulus- and cell type specific. Required for stability of MAP3K8. Involved in regulation of apoptosis in endothelial cells, promotes TEK agonist-stimulated endothelial survival. May act as transcriptional coactivator when translocated to the nucleus. Enhances CHUK-mediated NF-kappa-B activation involving NF-kappa-B p50-p65 and p50-c-Rel complexes.
Subcellular location: Cytoplasm, Nucleus
Synonyms: KLIP, ABIN2, FLIP1, TNFAIP3-interacting protein 2, A20-binding inhibitor of NF-kappa-B activation 2, ABIN-2, Fetal liver LKB1-interacting protein, TNIP2
Target Information: TNIP2 binds to the C-terminal zinc finger domain of A20 (TNFAIP3\, MIM 191163) and is involved in activation of the ERK (see MAPK3\, MIM 601795) MAP kinase pathway in various cell types (Van Huffel et al., 2001 [PubMed 11390377]\, Papoutsopoulou et al., 2006 [PubMed 16633345]).[supplied by OMIM, Mar 2008]